Lantheus (LNTH) Stock Forecast, Price & News

Lantheus (NASDAQ:LNTH) Frequently Asked Questions

Is Lantheus a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Lantheus stock.
View analyst ratings for Lantheus or view top-rated stocks.

When is Lantheus' next earnings date?

Lantheus is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for Lantheus.

How were Lantheus' earnings last quarter?

Lantheus Holdings, Inc. (NASDAQ:LNTH) posted its quarterly earnings results on Friday, April, 29th. The medical equipment provider reported $0.97 earnings per share for the quarter, topping analysts' consensus estimates of $0.46 by $0.51. The medical equipment provider earned $208.90 million during the quarter, compared to analysts' expectations of $165.30 million. Lantheus had a positive trailing twelve-month return on equity of 19.83% and a negative net margin of 6.89%. The business's quarterly revenue was up 125.8% on a year-over-year basis. During the same period last year, the firm earned $0.05 EPS.
View Lantheus' earnings history.

What guidance has Lantheus issued on next quarter's earnings?

Lantheus updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of $2.90-$3.15 for the period, compared to the consensus earnings per share estimate of $2.05. The company issued revenue guidance of $800.00 million-$835.00 million, compared to the consensus revenue estimate of $711.56 million.

What price target have analysts set for LNTH?

3 Wall Street analysts have issued 12 month target prices for Lantheus' stock. Their forecasts range from $75.00 to $94.00. On average, they expect Lantheus' stock price to reach $86.67 in the next twelve months. This suggests a possible upside of 35.8% from the stock's current price.
View analysts' price targets for Lantheus or view top-rated stocks among Wall Street analysts.

Who are Lantheus' key executives?

Lantheus' management team includes the following people:

• Ms. Mary Anne Heino, CEO, Pres & Director (Age 62, Pay $2.15M) (LinkedIn Profile)
• Mr. Robert J. Marshall Jr., CFA, CFO & Treasurer (Age 54, Pay $905.94k) (LinkedIn Profile)
• Mr. Daniel M. Niedzwiecki, Sr. VP, Gen. Counsel & Corp. Sec. (Age 45, Pay $627.1k)
• Mr. Etienne Montagut, Chief Bus. Officer (Age 47, Pay $607.99k) (LinkedIn Profile)
• Mr. Paul M. Blanchfield, Chief Commercial Officer (Age 41, Pay $734.54k)
• Ms. Andrea Sabens, Principal Accounting Officer (Age 43) (LinkedIn Profile)
• Mr. Mark Richard Kinarney, Sr. Director of Investor Relations
• Ms. Linda S. Lennox, VP of Corp. Communications & Chief of Staff (Age 57)
• Melissa Downs, Director of Corp. Communications
• Ms. Ying Yao, Chief HR Officer (Age 48)

What is Mary Anne Heino's approval rating as Lantheus' CEO?

4 employees have rated Lantheus CEO Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among Lantheus' employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Lantheus' key competitors?

Some companies that are related to Lantheus include Ipsen (IPSEY), Quidel (QDEL), Ortho Clinical Diagnostics (OCDX), Intellia Therapeutics (NTLA), Neogen (NEOG), Myriad Genetics (MYGN), Celldex Therapeutics (CLDX), Meridian Bioscience (VIVO), Heska (HSKA), Alpha Teknova (TKNO), VolitionRx (VNRX), VolitionRx (VNRX), Nymox Pharmaceutical (NYMX), OncoCyte (OCX) and MyMD Pharmaceuticals (MYMD).
View all of LNTH's competitors.

What other stocks do shareholders of Lantheus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include (MBBYF) (MBBYF), Energy Transfer (ET), Paratek Pharmaceuticals (PRTK), Catalyst Pharmaceuticals (CPRX), Amicus Therapeutics (FOLD), Anavex Life Sciences (AVXL), Exelixis (EXEL), Gerdau (GGB), Pieris Pharmaceuticals (PIRS) and Abeona Therapeutics (ABEO).

When did Lantheus IPO?

(LNTH) raised $75 million in an initial public offering on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.

What is Lantheus' stock symbol?

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

Who are Lantheus' major shareholders?

Lantheus' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (15.54%), Vanguard Group Inc. (8.37%), State Street Corp (3.48%), Dimensional Fund Advisors LP (2.42%), Lord Abbett & CO. LLC (1.89%) and William Blair Investment Management LLC (1.77%). Company insiders that own Lantheus stock include Andrea Sabens, Carol Walker, Daniel Niedzwiecki, Etienne Montagut, Gerard Ber, Heinz Christoph Maeusli, John J Bolla, Mary Anne Heino, Michael P Duffy, Michael P Duffy, Paul Blanchfield, Robert J Jr Marshall and Sam R Leno.
View institutional ownership trends for Lantheus.

Which institutional investors are selling Lantheus stock?

LNTH stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, William Blair Investment Management LLC, Russell Investments Group Ltd., Polar Asset Management Partners Inc., Peregrine Capital Management LLC, Reinhart Partners Inc., Velan Capital Investment Management LP, and Next Century Growth Investors LLC. Company insiders that have sold Lantheus company stock in the last year include Andrea Sabens, Carol Walker, Daniel Niedzwiecki, Etienne Montagut, Gerard Ber, John J Bolla, Mary Anne Heino, Paul Blanchfield, and Robert J Jr Marshall.
View insider buying and selling activity for Lantheus or view top insider-selling stocks.

Which institutional investors are buying Lantheus stock?

LNTH stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Lord Abbett & CO. LLC, Fuller & Thaler Asset Management Inc., Renaissance Technologies LLC, Hood River Capital Management LLC, Penn Capital Management Company LLC, Assenagon Asset Management S.A., and Arrowstreet Capital Limited Partnership.
View insider buying and selling activity for Lantheus or or view top insider-buying stocks.

How do I buy shares of Lantheus?

Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lantheus' stock price today?

One share of LNTH stock can currently be purchased for approximately $63.83.

How much money does Lantheus make?

Lantheus has a market capitalization of $4.38 billion and generates $425.21 million in revenue each year. The medical equipment provider earns $-71.28 million in net income (profit) each year or ($0.57) on an earnings per share basis.

How many employees does Lantheus have?

Lantheus employs 612 workers across the globe.

What is Lantheus' official website?

The official website for Lantheus is www.lantheus.com.

How can I contact Lantheus?

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at (978) 671-8001, via email at [email protected], or via fax at 978-671-8860.